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BioavailabilityAbstract Nelﬁnavir mesylate (NFV) is an anti-viral drug, used in the treatment of Acquired
Immunodeﬁciency Syndrome (AIDS). Poor oral bioavailability and shorter half-life (3.5–5 h)
remain a major clinical limitation of NFV leading to unpredictable drug bioavailability and fre-
quent dosing. In this context, the objective of the present study was to formulate NFV loaded poly
(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs), which can increase the solubility and oral
bioavailability along with sustained release of the drug. NFV loaded PLGA-NPs were prepared
by nanoprecipitation method using PLGA and Poloxomer 407. The prepared NPs were evaluated
for particle size, zeta potential, morphology, drug content, entrapment efﬁciency (EE) and in vitro
dissolution studies. Oral bioavailability studies were carried out in New Zealand rabbits by
administering developed NFV PLGA-NPs and pure drug suspension. PLGA-NPs prepared by
using 1:4 ratio of drug and PLGA, with a stirring rate of 1500 rpm for 4 h. The prepared NPs were
in the size of 185 ± 0.83 nm with a zeta potential of 28.7 ± 0.09 mV. The developed NPs were
found to be spherical with uniform size distribution. The drug content and EE of the optimized
formulation were found to be 36 ± 0.19% and 72 ± 0.47% respectively. After oral administration
of NFV PLGA-NPs, the relative bioavailability was enhanced about 4.94 fold compared to NFV
668 D.N. Venkatesh et al.suspension as a control. The results describe an effective strategy for oral delivery of NFV loaded
PLGA NPs that helps in enhancing bioavailability and reduce the frequency of dosing.
ª 2015 TheAuthors. Production and hosting by Elsevier B.V. on behalf ofKing SaudUniversity. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Human Immunodeﬁciency Virus/Acquired Immunodeﬁciency
Syndrome (HIV/AIDS) is the major health issue among the
public world-wide (WHO, 2014b). According to the World
Health Organization (WHO), there are about 35 million peo-
ple globally suffering from HIV/AIDS as of the year 2013.
The report also says that around 2.3 million people were
infected with HIV among which 260,000 are children
(UNAIDS, 2013). The patients with HIV/AIDS are typically
treated with High Activity Antiretroviral Therapy
(HAART), which involves the chronic administration of at
least three combined antiretroviral drugs. However, this ther-
apy can only suppress viral replication temporarily (WHO,
2014a). The prolonged HAART therapy showed a low patient
compliance, especially among the children. The approved anti-
retroviral drugs by regulatory agencies for pediatric use are in
fact limited (Sosnik et al., 2012). Nelﬁnavir mesylate (NFV) is
a non-peptidic HIV-1 protease inhibitor, which is the ﬁrst of its
kind recommended for pediatric use (Schuval, 2009). NFV is
one of the several currently available protease inhibitors which
is used to suppress viral replication and to improve the
immune function in HIV-infected individuals. Typically,
NFV along with other antiretroviral agents are administered
in HAART (Bardsley-Elliot and Plosker, 2000). Based on bio-
pharmaceutical classiﬁcation, NFV belongs to class IV drug,
which has low aqueous solubility and low permeability. It is
highly lipophilic (logp= 6.0) and almost insoluble [at pH
7.4 (very low), at pH 3.5 (0.5 mg/mL)] and non-ionizable
in water. The usual dosing regimen of NFV by conventional
dosage form has a shorter half-life of 3.5–5 h, which demands
its frequent administration three times a day. By incorporating
into Nano particulate carrier and administering it by oral
route it might enable the drug to present in system for longer
period of time due to its sustained/controlled drug delivery
with enhanced bioavailability (Sahoo and Labhasetwar,
2003). Nanoencapsulation promotes controlled drug release
and drug targeting, which consecutively improves drug solubil-
ity and protects the molecules from premature degradation.
Nanoparticles (NPs) enhance speciﬁcity, tolerability, drug efﬁ-
cacy and therapeutic index. The pharmacokinetic parameters
of the drug are altered when it is formulated as NPs.
Improved plasma circulation time by improved absorption
and bioavailability is usually seen with reduced clearance.
The physicochemical parameters of NPs viz., surface modiﬁca-
tion charge, particle size and hydrophobicity signiﬁcantly
inﬂuences the drug’s pharmacokinetics, impacting the drug’s
bioavailability and especially the biodistribution (Khalil
et al., 2013). In recent years, nano-based drug delivery systems,
such as polymeric NPs, have demonstrated the apparent
advantages in improving pharmacological activities and oral
bioavailability of poorly soluble drugs (Agu¨eros et al., 2010).
For instance, NPs of synthetic polymers such as PLGA areregularly utilized due to its versatility and biocompatibility in
encapsulating variety of drugs (Anderson and Shive, 2012;
Jain, 2000; Panyam and Labhasetwar, 2003). Oral delivery of
PLGA NPs is also been well studied (Damge´ et al., 1996).
Encapsulation of drugs in PLGA Nano-carriers reduces the
undesirable effects of the drug, such as short circulation half-
life and non-site speciﬁc targeting, thereby reducing systemic
side effects. These drug-loaded PLGA NPs prolong the sys-
temic circulation time by sustained release (Lu¨ et al., 2009).
Several disease-related drugs/bioactive molecules are success-
fully encapsulated using PLGA to control the drug delivery
and to improve the bioavailability (Kumari et al., 2010).
Thus, these unique nanoparticulate carrier systems have the
potential to change the current scenario of research and
diagnosis in real time (Ferrari, 2005). Hence, in the present
study, an attempt was made to develop nanotechnology
based systems, for a poorly water soluble drug NFV
using PLGA as polymer, which is expected to improve the
dissolution properties of the drug and thereby increasing the
bioavailability.
2. Materials and methods
2.1. Materials
Nelﬁnavir mesylate (99.5%) was obtained as a gift sample
from Glenmark Pharmaceuticals Ltd (Mumbai, India).
Darunavir was obtained as a gift sample fromMylan laborato-
ries (Hyderabad, India). PLGA was purchased from Evonik
Degussa India Pvt Ltd (Mumbai, India). Poloxomer 407 was
purchased from Sigma life sciences (Mumbai, India). The
HPLC grade water was prepared by using Milli-Q Academic,
Millipore (Bangalore, India). All other chemicals used in this
study were of analytical grade.2.2. Methods
2.2.1. Preparation of NFV PLGA NPs (Bilati et al., 2005; Kim
et al., 2011; Shah et al., 2009)
NPs of PLGA containing NFV were prepared by nanoprecip-
itation method reported elsewhere with some modiﬁcations.
20 mg of the drug and 100 mg of polymer (PLGA) (50:50) were
dissolved in 5 ml of acetonitrile (Solution A). 125 mg of
Poloxomer F-127 was dissolved in 50 ml of deionized water
(Solution B). Solution A was added to Solution B using a syr-
inge at the ﬂow rate of 1 mL/10 min by magnetic stirring
(1500 rpm) at room temperature. From above method, ﬁve dif-
ferent batches of NFV PLGA-NPs were prepared with various
concentrations of PLGA and coded as F1–F5. The obtained
nanosuspension was centrifuged, lyophilized with cryoprotec-
tant (2% sucrose) and subjected for various characterization
parameters.
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et al., 2014; Govender et al., 1999; Song et al., 2008)
To separate NPs, the nanosuspension was ultra-centrifuged
using Remi Laboratory Centrifuge (REMI – Model R-8C,
India) at 93,000g for 1 h. The obtained supernatant was
removed and the NPs were collected. The collected NPs were
dissolved in 5 mL of acetonitrile and then 10 mL of methanol
was added to precipitate the polymer. Then the samples were
ﬁltered through 0.22 l millipore membrane ﬁlter and the
amount of drug was estimated by HPLC. Lyophilized NFV-
PLGA-NPs (1–2 mg) were dissolved in 1 mL of methanol
aimed at complete extraction for the loading and encapsulation
detection. The samples in methanol were gently shaken on a
shaker for 24 h at 37 C to leach out NFV entirely. Then the
solutions were centrifuged at 13,500 rpm for 10 min, and super-
natant was collected. The supernatant (100 lL) was diluted to
2 mL. An aliquot of 20 lL was used for HPLC analysis, as
described in ‘Section 2.4.2’. The amount of NFV loaded and
encapsulated in nanoparticles was expressed as loading efﬁ-
ciency or encapsulation efﬁciency calculated as follows.
Drug loadingð%w=wÞ¼ Mass of drug in nanoparticle
Mass of nanoparticle recovered
100
Entrapment efficiency
¼ Mass of the drug in nanoparticle
Mass of the drug used in the formulation
 1002.2.3. Characterization of NPs
2.2.3.1. Particle size determination (Betancourt et al., 2007).
The developed NPs were washed with double distilled water
(ﬁltered through 0.22 l) several times before particle size
analysis. Samples were analyzed using Zeta Sizer 2000
(Malvern instrument, UK) which allows sample measurement
in the range of 0.02–2000.00 lm and particle size distribution.
2.2.3.2. Differential Scanning Calorimetry (DSC) (Kashi et al.,
2012). DSC analysis was performed using DSC Q200, (TA
Instruments, USA). The samples were heated in sealed alu-
minum pans at a rate of 10 C per min in a 30–300 C tempera-
ture under nitrogen ﬂow of 40 mL/min.
2.2.3.3. Scanning electron microscopy (SEM) (O¨zbas-Turan
and Akbug˘a, 2011). SEM was used to verify the uniformity of
particle shape and size. Freeze-dried NPs were re-suspended
in distilled water and later dropped into a silicon grid and
dried at room temperature. The NPs suspension was vacuum
coated with gold for 3 min. The surface morphology of the
samples was observed under a scanning electron microscope
(JEOL ltd, Japan) operated at 15-keV pulse at different
resolutions.
2.2.3.4. Transmission electron microscopy (TEM) (Peter
Christoper et al., 2014). To study the external morphology
by TEM (100s, JEOL Ltd, Japan), the prepared NPs were
freeze dried and lyophilized. Freeze dried NPs were then
diluted with 2 mL of distilled water and evenly mixed by
sonication for 2 min. The samples were prepared by placing
a drop of the NPs suspension on the Formvar coated copper
grid and air dried.2.2.3.5. X-ray diffraction (XRD) studies (Kim et al., 2011). An
XRD peak mainly depends on the crystal size as they indicate
the crystalline nature at particular value at 2h range.
Molecular arrangements of NFV alone and in nanoparticulate
formulations were performed using an X-ray diffractometer
(PANalytical X’pert PRO, The Netherlands) using Cu Ka
radiation. The data were collected over an angular range from
3 to 50 degrees 2h in continuous mode using a step size of 0.02
degree 2h and step-time of 5 s.
2.3. In vitro release studies (Asadi, 2014; Seju et al., 2011)
The dialysis bag diffusion technique was used to study the
in vitro drug release of NFV from NPs. The drug loaded
NPs were placed in the dialysis bag and immersed into
250 mL of HCl pH (1.2) at 100 rpm for 24 h. The entire system
was kept at 37 ± 0.5 C with continuous magnetic stirring.
Samples were withdrawn from the receptor compartment at
predetermined intervals (0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12
and 24 h) and replaced with fresh medium to maintain sink
conditions. The amount of drug release was analyzed by
HPLC. In order to elucidate the mode and mechanism of drug
release, the in vitro data were transformed and interpreted by a
graphical interface constructed using zero order, First order,
Higuchi’s and Peppas’s equation respectively.
2.4. In vivo bioavailability studies (Ghosh, 2007; Ma et al.,
2012)
2.4.1. Estimation of drug in rabbit plasma
All the animal investigations were performed as per the
requisite protocol approved by the Institutional Animal
Ethic Committee of JSS College of Pharmacy, Ooty,
India. (Approval/Letter no. JSSCP/IAEC/M.PHARM/
PH.ANALYSIS/01/2012-13). Healthy New Zealand rabbits
weighing 2.0–2.5 kg were kept in individual cages for 30 days
prior to the study in the departmental animal house for the
purpose of acclimatization. The animals had free access to
water and food. A constant day and night cycle was main-
tained and the temperature of the animal room was kept con-
stant throughout the period. The animals were divided into 3
groups containing six animals in each group. The dose for
the rabbits (35 mg/kg) was selected based on the surface area
ratio of rabbit and man. Group 1 animals were treated with
pure drug, Group 2 animals were treated with NFV loaded
NPs and Group 3 was pertained to be control. Immediately
after drug administration the animals were given 5 mL of
water. Blood samples each not more than 0.5 ml were with-
drawn from the marginal ear vein at 0, 0.5, 1, 1.5, 2, 3, 4, 6,
8, 10, 12 and 24 h period using a sterilized syringe. Zero hour
fasting blood samples were withdrawn early in the morning.
The blood samples were collected in Ria-vials containing
anticoagulant (100 lL of 11% sodium citrate) and were cen-
trifuged at 4000 rpm for 15 min to separate plasma and then
stored at 20 C. The plasma samples were deproteinized by
mixing the samples with equal volume of 10% perchloric acid
and the contents were vortex mixed for 2 min. It was then
centrifuged at 4000 rpm for 15 min and the supernatant liquid
was separated and analyzed. Estimation of plasma samples by
HPLC was carried out at optimized chromatographic
Figure 1 Representative chromatograms corresponding to (a)
NFV loaded PLGA NPs with IS (Darunavir) and blank PLGA
NPs and (b) NFV spiked in rabbit plasma with IS (Darunavir) and
processed blank rabbit plasma.
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matograms are shown in Fig. 1.
2.4.2. Analytical conditions
Quantiﬁcation of NFV in NPs and plasma samples was per-
formed using Shimadzu HPLC (Kyoto, Japan) with a PDA
detector. The analysis was performed on a Luna C18 column
(150 · 4.6 mm, 5l) (Phenomenex, USA) by employing a
mobile phase comprising KH2PO4: acetonitrile (40:60) at a
pH of 4.0 which was delivered at a ﬂow rate of 1.0 mL/min.
The analytes were detected photometrically at 249 nm. Data
acquisition and processing were done by using LC Solutions
software (SP 1.1). Darunavir was used as internal standard
(IS), as it belongs to the same class of drugs and presented
acceptable resolution with that of NFV. The retention time
of NFV was 5.0 min and IS was 3.1 min. The plotted calibra-
tion curves were linear in the concentration range of 1–50 lg/
mL (r= 0.999) in NPs and 10–500 ng/ml (r= 0.999) in rabbit
plasma. The intra and inter-day accuracy and precision were
within R.S.D 6 8%. The extraction efﬁciency in case of spiked
plasma samples was 97.5 ± 2.3%.2.5. Statistical analysis
Statistical data were analyzed using GraphPad Prism 6 pro-
gram (Graph pad Inc., USA). Results are expressed as
mean ± SD for the number of observations indicated. Mean
values were compared using one-way analysis of variance
(ANOVA) followed by Tukey post hoc test to compare means
between the different treatment groups. Differences were con-
sidered signiﬁcant at p< 0.05 unless otherwise stated. The
amount of drug in the receptor compartment (in vitro) and
in plasma (in vivo) was estimated through HPLC. The relative
oral bioavailability of NFV was calculated according to the
equation:
Relative BAð%Þ ¼ 100 ðAUCA=doseBÞðAUCB=doseAÞ
AUCA and AUCB represent the area under the blood concen-
tration time curve of NFV-PLGA-NPs and NFV suspension,
and doseA and doseB mean the dose of NFV-PLGA-NPs
and NFV suspension following oral administration.
3. Results and discussion
3.1. Preparation
The NFV loaded PLGA NPs were prepared by employing
nanoprecipitation method, as it appeared to be simple and
appropriate. The carrier capacity of PLGA relating to NFV
was determined by preparing ﬁve batches of drug-loaded
NPs, by varying the concentration of polymer to a constant
amount of drug (Table 1). During the procedure, an increase
in polymer concentration increased the size of the NPs and
entrapment efﬁciency. But after reaching a concentration of
200 mg, the saturation rate and entrapment of the drug to that
of polymer were decreased. The stirring rate showed a
signiﬁcant inﬂuence on the size of NPs, i.e., at higher stirring
rate (1500 rpm) the NPs particle size was reduced
(185 ± 0.83 nm) whereas at lower stirring rate (500 rpm) the
particle size of NPs (842 ± 0.68 nm) was not reduced
effectively.
3.2. Drug loading and entrapment efﬁciency
Drug loading and entrapment efﬁciency of all NPs made of
different concentration were shown in Table 1. Among all
the batches, F4 batch was found to have higher entrapment
efﬁciency (72 ± 0.47%) and drug loading (36 ± 0.19%) and
hence it was chosen as ideal and preceded for further studies.
Drug loading has a very important inﬂuence in the polymeric
NPs preference over others such as solid lipid NPs. The impro-
per entrapment leads to the initial burst of the NPs, which hin-
ders its sustained release property.
3.3. Determination of particle size and zeta potential
(Betancourt et al., 2007)
The mean particle size of NFV NPs was found to be 185 nm
(Fig. 2a) and the zeta potential was found to be +28.7 mV
(Fig. 2b). The experiment was performed in three replicate
(n= 3) in order to ensure reproducibility and minimize the
Table 1 Particle size, entrapment efﬁciencies and drug loading (%) of Nelﬁnavir PLGA polymeric nanoparticles.
Formulation code Drug: polymer ratio Particle size (nm) Entrapment eﬃciency (%) Drug loading (%)
F1 1:1 192.8 ± 0.72 20 ± 0.09 10 ± 0.018
F2 1:2 140.3 ± 0.28 27.5 ± 0.03 17.5 ± 0.027
F3 1:3 167 ± 1.01 46 ± 0.87 23 ± 0.038
F4 1:4 185.3 ± 0.83 72 ± 0.47 36 ± 0.19
F5 1:5 203.2 ± 0.47 58 ± 0.93 29 ± 1.25
Figure 2 DSC curves of NFV, PLGA, and NFV-PLGA-NPs.
Figure 3 (a) Particle size of NFV-PLGA-NPs and (b) zeta
potential of NFV-PLGA-NPs.
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0.2, which shows that the system has a relatively narrow dis-
tribution. The zeta potential of the prepared NPs is the promi-
nent factor to ensure stability. Highly charged NPs are capable
to remain stable as colloidal suspension. Since the prepared
NPs have shown high zeta potential, this ensures the stability
of the formulation.
3.4. DSC
DSC studies were done to assess the interaction between the
drug and the polymer. Thermogram of NFV, PLGA and
NFV PLGA NPs was illustrated in Fig. 3. The DSC curve
of NFV showed an endothermic peak at temperature of
97 C, corresponding to its melting point. PLGA has showed
a peak at 54 C. NFV-PLGA polymeric NPs have shown a
major peak at 65 C and the peak position of NFV was found
to be disappearing, which can be attributed to the entrapment
of drug in the NPs. This also has the chance of entrapment ofdrug inside the polymer in polymeric NPs. The DSC studies
support the rationale of stability as it is the primary concern,
which can affect the formulation in many ways.
3.5. SEM and TEM
SEM and TEM were performed to obtain more information
on the particle size, morphology and aggregation phenomena.
The image of prepared polymeric NPs has shown that the for-
mulated NPs were of spherical in shape with size ranging from
100 nm to 500 nm (Fig. 4). The NPs were observed with
smooth surface, which may contribute to its release of the drug
in a sustained manner, when compared to the NPs having
rough surface.
3.6. XRD studies
To understand the nature of the nanoparticle-encapsulated
NFV, XRD pattern of pure NFV and NFV-loaded PLGA-
NPs was studied. In this study, NFV pure drug has shown a
sharp, single highest peak at 2h equals 22.600, which implies
its crystalline nature. The diffractogram of NFV loaded
PLGA-NPs was found to be different from the pure drug
(Fig. 5). The intensity and number of peaks reduced in NFV
loaded PLGA-NPs indicate, the maximum NFV was
entrapped inside the PLGA-NPs, since the decrease in inten-
sity of the peak can be attributed to lower level of detecting
the encapsulated drug which is dispersed in molecular level.
This also further indicates the amorphous state of the encapsu-
lated NFV.
Figure 4 (a) SEM photographs of NFV-PLGA-NPs and (b)
TEM photographs of NFV-PLGA-NPs.
Figure 5 XRD of NFV, PLGA and NFV-PLGA-NPs.
Figure 6 Release rates of NFV from PLGA NPs in vitro in HCl
buffer pH 1.2 (mean ± SD, n= 3).
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The cumulative percentage release proﬁle of NFV from F4
NPs batch shown in Fig. 6. This was plotted using Graph
pad Prism software (v. 5.01) on a Microsoft Windows 7 workstation. A slow release of NFV from NPs was observed at pH
1.2 HCl buffer which was sustained up to 24 h at 37 ± 0.5 C.
It was further observed that there was no signiﬁcant burst
release which may be due to the total drug entrapped inside
the polymer. The NPs showed a comparatively high percentage
drug release (92.80%) over a period of 24 h and the n value
was found to be 1 (limits 0.45–1) which shows the mechanism
of drug release is by non-Fickian (anomalous) solute diffusion
(Korsmeyer et al., 1983). When NPs were kept in a release
solution, the PLGA was dissolved gradually to form holes or
disintegrated to release the drug. This release of drug from
the NPs mainly depends on concentration of the polymer.
The compact nature of the polymer coat around the drug sus-
tains the drug release. Particle size is another phenomenon
which determines the rate of dissolution and solubility. It
has been known that the particle size is inversely proportional
to rate of dissolution and hence a higher rate of dissolution
was observed with the developed NPs (Asadi, 2014; Ma
et al., 2012).
3.8. In vivo data analysis
NFV suspension and NFV loaded PLGA-NPs were orally
administered to male New Zealand rabbits. The plasma con-
centration vs. time curve is shown in Fig. 7. Table 2 shows
the pharmacokinetic parameters (peak concentration, time to
reach peak concentration, area under the curve 0–24, half-life,
and relative bioavailability) of NFV after oral administration
in suspension as well as in PLGA-NPs. A remarkable increase
in plasma concentration of NFV was observed when NPs
group was studied by comparing with control group. The
Cmax of pure drug in suspension form was
0.0190 ± 0.055 lg/mL at 1.5 h and for PLGA-NPs it was
found to be 0.04590 ± 0.021 lg/mL at 4 h. These results imply
a signiﬁcant difference in bioavailability between NFV suspen-
sion and NFV loaded PLGA-NPs. The AUC0–24 value for the
developed NPs containing NFV was found to be higher
(0.374 ± 0.069 h lg/mL) compared to pure drug in suspension
(0.076 ± 0.043 h lg/mL). These results also clearly demon-
strate that the PLGA-NPs greatly improved bioavailability
for NFV. The reasons are many, but among the most salient
is the nano-based drug delivery system. On the one hand, par-
ticles that are nanoscale in size are easily absorbed into the
folds of the intestinal wall, while larger particle surface area
to volume lends itself to rapid drug dissolution (Ma et al.,
Figure 7 Mean plasma concentration time proﬁles of NFV in
rabbits: (a) NFV suspension and (b) NFV NPs with (mean ± SD,
n= 6).
Table 2 Pharmacokinetic parameters of Nelﬁnavir after oral
administration of NFV loaded PLGA NPs and suspension at
the dose of 35 mg/kg.
Parametersa NFV suspension
(mg/kg)
NFV PLGA-NPs
(mg/kg)
Cmax (lg/mL) 0.0190 ± 0.055 0.04590 ± 0.021
AUC0–24 (h lg/mL) 0.076 ± 0.043 0.374 ± 0.069
t1/2 (h) 6.66 ± 1.25 19.8 ± 2.09
tmax (h) 1.50 ± 0.056 4.12 ± 0.091
Frel (%) – 494.4
a Cmax, peak concentration; AUC, area under the curve; t1/2, half-
life; tmax, time to reach peak concentration; Frel, relative
bioavailability.
Fabrication and in vivo evaluation of Nelﬁnavir loaded PLGA nanoparticles 6732012). As shown in Table 2, NFV PLGA-NPs showed the
longer half-life of 19.8 ± 2.09 h compared to NFV suspension
(6.66 ± 1.25 h) due to the principally associated prolonged
absorption phase and sustained release of PLGA-NPs.
Finally, the relative bioavailability of NFV-PLGA NPs was
calculated to be 494.4% compared to NFV suspension group
indicates PLGA-NPs achieved markedly better absorption of
NFV compared with the suspension. These results verify that
PLGA-NPs were effective in improving the oral bioavailability
of NFV. In summary, the developed NFV PLGA-NPs had
high plasma concentration, low clearance, long half-life, and
higher relative bioavailability compared to NFV in suspension.
4. Conclusion
NFV loaded PLGA-NPs were successfully prepared by nano-
precipitation method. In this work, the inﬂuence of various
process parameters on entrapment efﬁciency and particle size
was systemically evaluated. The developed NFV loaded
PLGA-NPs were spherical in shape with uniform size dis-
tribution and particle size of <200 nm. The prepared NPs
were evaluated both in vitro and in vivo. The drug release
was sustained up to 24 h from PLGA-NPs. After oral
administration of NFV PLGA-NPs, the relative bioavailability
was enhanced about 4.94-fold and had a longer half-life
compared with that of NFV in suspension. The developed
PLGA-NPs also exhibited a longer time to reach the peak con-
centration (tmax) than the drug in suspension form and
appeared to be more consistent in overall performance.Based on these observations, it was concluded that the formu-
lated PLGA-NPs containing NFV showed an increase in oral
bioavailability and are capable of exhibiting sustained release
over a period of time as compared to pure drug in the suspen-
sion form. Hence, PLGA-NPs were found to be a promising
drug delivery system in encapsulating hydrophobic drugs like
NFV for improved oral bioavailability with sustained release.
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